Published in Glycobiology on December 11, 2009
Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer (2015) 2.00
The analysis of sialylation, N-glycan branching, and expression of O-glycans in seminal plasma of infertile men. Dis Markers (2015) 1.38
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem (2010) 1.16
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Anal Chem (2011) 1.15
Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. Theranostics (2015) 0.96
Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer. Front Oncol (2015) 0.91
Analytical glycobiology at high sensitivity: current approaches and directions. Glycoconj J (2012) 0.90
The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med (2013) 0.88
Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. J Proteome Res (2011) 0.85
Integration of the transcriptome and glycome for identification of glycan cell signatures. PLoS Comput Biol (2013) 0.85
Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics (2016) 0.82
Directed evolution of lectins with sugar-binding specificity for 6-sulfo-galactose. J Biol Chem (2012) 0.81
Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. Clin Chem (2012) 0.81
Fucosyltransferase 1 mediates angiogenesis in rheumatoid arthritis. Arthritis Rheumatol (2014) 0.78
Expression of LacdiNAc groups on N-glycans among human tumors is complex. Biomed Res Int (2014) 0.77
Application of cancer-associated glycoforms and glycan-binding probes to an in vitro diagnostic multivariate index assay for precise diagnoses of cancer. Proteomics (2016) 0.76
HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma. Sci Rep (2017) 0.75
Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application. EJIFCC (2014) 0.75
Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer. Int J Mol Sci (2017) 0.75
Terminal Mannose Residues in Seminal Plasma Glycoproteins of Infertile Men Compared to Fertile Donors. Int J Mol Sci (2015) 0.75
Biotinylated N-Acetyllactosamine- and N,N-Diacetyllactosamine-Based Oligosaccharides as Novel Ligands for Human Galectin-3. Bioengineering (Basel) (2017) 0.75
Generation of pluripotent stem cells from neonatal mouse testis. Cell (2004) 3.95
Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int (2006) 2.37
Current use of the artificial urinary sphincter and its long-term durability: a nationwide survey in Japan. Int J Urol (2009) 1.96
Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology (2011) 1.65
L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int (2009) 1.57
High molecular mass proteome of androgen-independent prostate cancer. Proteomics (2005) 1.54
Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys (2006) 1.50
Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. Int J Urol (2010) 1.47
The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun (2009) 1.45
Predictors of benign histology in clinical T1a renal cell carcinoma tumors undergoing partial nephrectomy. Int J Urol (2013) 1.42
Bone dissemination of prostate cancer after holmium laser enucleation of the prostate: a case report and a review of the literature. Int J Urol (2013) 1.41
Surgical outcome of laparoscopic radical prostatectomy: summary of early multiinstitutional experience in Japan. Int J Clin Oncol (2003) 1.38
Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell (2012) 1.35
Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res (2010) 1.21
Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties. Exp Cell Res (2007) 1.20
Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol (2003) 1.16
The endoscopic surgical skill qualification system in urological laparoscopy: a novel system in Japan. J Urol (2006) 1.13
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol (2010) 1.11
Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol (2006) 1.10
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int (2009) 1.06
Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology (2006) 1.05
Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology (2002) 1.04
Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology (2002) 1.03
Structural basis for recognition of high mannose type glycoproteins by mammalian transport lectin VIP36. J Biol Chem (2007) 1.02
High-affinity binding of recombinant human galectin-4 to SO(3)(-)-->3Galbeta1-->3GalNAc pyranoside. Glycobiology (2002) 1.02
Galectin-8-N-domain recognition mechanism for sialylated and sulfated glycans. J Biol Chem (2011) 1.00
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol (2010) 0.99
The N-terminal carbohydrate recognition domain of galectin-8 recognizes specific glycosphingolipids with high affinity. Glycobiology (2003) 0.98
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther (2006) 0.98
Involvement of VIP36 in intracellular transport and secretion of glycoproteins in polarized Madin-Darby canine kidney (MDCK) cells. J Biol Chem (2002) 0.97
Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology (2007) 0.97
Primary squamous cell carcinoma of the seminal vesicle. Urology (2002) 0.97
The role of caveolin-1 in androgen insensitive prostate cancer. J Urol (2002) 0.97
Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol (2011) 0.96
Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett (2008) 0.96
Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys (2009) 0.96
Cavernous hemangioma of the adrenal gland. Int J Urol (2009) 0.96
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int (2010) 0.96
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med (2011) 0.96
Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody. Glycobiology (2011) 0.95
Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology (2008) 0.95
Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology (2005) 0.95
[Spontaneous cervical epidural hematoma presenting with hemiparesis following neck extension: a case report]. No Shinkei Geka (2008) 0.94
[Superficial bladder cancer with lung metastasis without local invasion: a case report]. Hinyokika Kiyo (2007) 0.94
Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer (2003) 0.94
Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis (2013) 0.94
Predictive factors for overall quality of life in patients with advanced cancer. Support Care Cancer (2013) 0.94
Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. Int J Urol (2003) 0.93
A Caenorhabditis elegans glycolipid-binding galectin functions in host defense against bacterial infection. J Biol Chem (2009) 0.93
Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells. J Biol Chem (2004) 0.93
Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract (2002) 0.92
Bone marrow engraftment but limited expansion of hematopoietic cells from multipotent germline stem cells derived from neonatal mouse testis. Exp Hematol (2009) 0.92
Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res (2004) 0.92
Histopathologic and biologic characteristics of a transitional cell carcinoma with inverted papilloma-like endophytic growth pattern. Urology (2003) 0.91
Activation of beta1,3-N-acetylglucosaminyltransferase-2 (beta3Gn-T2) by beta3Gn-T8. Possible involvement of beta3Gn-T8 in increasing poly-N-acetyllactosamine chains in differentiated HL-60 cells. J Biol Chem (2008) 0.91
Identification of cardiac stem cells with FLK1, CD31, and VE-cadherin expression during embryonic stem cell differentiation. FASEB J (2005) 0.90
Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer. Radiother Oncol (2006) 0.89
Prostatic cystadenoma presenting as a large multilocular mass. Int J Urol (2002) 0.89
Recognition by TNF-alpha of the GPI-anchor glycan induces apoptosis of U937 cells. Arch Biochem Biophys (2004) 0.89
Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int (2008) 0.89
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World J Urol (2012) 0.88
Characterization of a novel galactose beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8): the complex formation of beta3Gn-T2 and beta3Gn-T8 enhances enzymatic activity. Glycobiology (2005) 0.88
The binding of VIP36 and alpha-amylase in the secretory vesicles via high-mannose type glycans. Glycobiology (2004) 0.88
Roles of angiogenic factors and endothelin-1 in gastric ulcer healing. Clin Sci (Lond) (2002) 0.88
[Anaphylactoid purpura after intravesical therapy using bacillus Calmette-Guerin for superficial bladder cancer]. Hinyokika Kiyo (2008) 0.88
Factors contributing to long graft survival in non-heart-beating cadaveric renal transplantation in Japan: a single-center study at Kitasato University. Clin Transplant (2002) 0.88
Differences between intraoperative ultrasound-based dosimetry and postoperative computed tomography-based dosimetry for permanent interstitial prostate brachytherapy. Brachytherapy (2010) 0.88
High-intensity focused ultrasound therapy for prostate cancer. Int J Urol (2011) 0.88
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys (2011) 0.88
Essential roles of 3'-phosphoadenosine 5'-phosphosulfate synthase in embryonic and larval development of the nematode Caenorhabditis elegans. J Biol Chem (2006) 0.87
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res (2013) 0.87
Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology (2002) 0.87
Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. J Sex Med (2011) 0.87
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol (2007) 0.87
Ammonium acid urate urolithiasis in Japan. Int J Urol (2006) 0.87
Profilin 1 overexpression in renal cell carcinoma. Int J Urol (2010) 0.86
Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res (2002) 0.86
Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol (2011) 0.86
Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med (2012) 0.86
Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty. Int J Urol (2003) 0.86